Heme Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Question | Answer |
Normal Platelet count | 400,00-150,00/microliter |
Thrombocytopenia | <100,000/microliter |
Pseudothrombocytopenia | false low cause by EDTA, cold, or hard venipuncture. |
Bleeding time | Plt f(x)', nl 7.5-25 minutes, elevated in thrombocytopenia too. NOT in Factor deficiencies!!! |
Aggregation studies | Indicated for normal plt count, elevated bleeding time; aggregation: epi, adp, collagen; Adhesion: ristocetin |
May-Hegglin Anomlay | Autosomal Dominant(MYH9:non-muscle myosin in heaveychain IIa; allows for normal plt size); Thrombocytopenia(spleen destruction), large plt, mild to mod. bruise, bleeding in surgery, High mean plt volume. |
Wiskott-Aldrich Syndrome | x-linked; Thrombosytopenia(small plt); assoc. with immunodeficiency(no IgM) and eczema(1st indicator); severe bleeding w/ surgery, trauma, and mense. (rare) |
Congenital Amegakaryocytic | Autosomal recessive; Plt GF receptor mutation. Megakaryocytes die without GF. Tx is BM transplant |
Diseases that decrease the production of Plts | Rubella, HIV |
Drugs that suppress Plt productions | Thiazide diuretics, Diethylstillberstrol, ethanol, and tolbutamide |
Immune mediated thrombocytopenia(drugs) | Procainamide, Quinidine, Heparin(late): abs to plt factor 4 heparin complex on plt surface 3-5 days after first admin, less likely with LMW hep |
Plt aggregation thrombocytopenia(drugs) | Protamine, Heparin(early) |
ITP - General | Autoimmune; ab to 2,3, ba or 1b; Spleen destruction, virally self-limiting in child; chronic and non resolving in adults(spontaneous); |
ITP - Manifestations | Manifest: petechiae, bruises, epistaxis, gums, GI bleed and hematuria(less common), IC hemmorrhage(rare). |
ITP - Diagnosis | CBC: thrombocytopenia, all others nl; large plts, possible anemia(blood loss), Evan's Syndrome: autoimmune hemolutic anemia w/ reticulocytes and spheocytes. |
ITP - management | Predinsone 1-2mg/kg/24hrs; splenectomy, Ig 1g/kg; refractory: danazol, chemo |
TTP - General | (lymphomas and SLE) Immune mediated thrombocytopenia. ab against vW cleaving protease (adamts13). Long vW shred RBC, consume and consume plts and gets stuck in microvascular |
TTP - Manifestations | Anemia: fatigue, pale, SOB on excertion; Bleeding: petechiae, purpura, pallor; Neurolgoical symptoms: headache. |
TTP - Diagnosis | CBC: anemia, reticulocytes, schistocytes, thrombocytopenia; inc. bilirubin(hemolysis); LDH elevated but less than expected(hemolysis); coag test normal. |
TTP - management | plasmapharesis, FFP, predisone, |
HUS - Pathogenesis | Thrombocytopenia; endotheliacell dysfunction(e.coli invasion releases agglutinating factor; infancy and childhood;Micorangiopathic hemolytic anemia; thrombocytopenia(consume; renal failure(most common cause in child);Elevated LDH out of proportion;Coag:nl |
HUS - Manifestation | anemia; bleeding, renal failure; rare neurologic manifestations |
HUS - Diagnosis | Hemolytic anemia, thrombosytopenia(less severe TTP); LDH elevated; coombs test: -; coag: norm. |
HUS - syndrome | Children: self-limiting; pallative; Adult: plasmapharesis, FFP. |
Plt destruction non immune mediated Preggers | pre-eclampisa: low plt, htn, edmea, proteinuira; Hemolysis elevated liver enzyme and low plts |
Causes of Hypersplenism(thrombocytopenia) | Tumor, anemia, malaria, tb, portal hypertension, leukemias/omas |
Bernard-Soulier Syndrome - general | autosomal recessive - deficient 1b |
Bernard-Soulier Syndrome - manifestations | Sever bleeding |
Bernard-Soulier Syndrome - Diagnosis | thrombocytopenia; large plts, bleeding time prolonged; ristoceiten: abn; adp: ok; |
Bernard-Soulier Syndrome - management | Plt transfusions(no cure) |
Glandzman Thrombasthenia - General | autosomal recessive, deficient 2b3a, |
Glandzman Thrombasthenia - manifestations | mucosal and surgical bleeding(not as severe as BSS) |
Glandzman Thrombasthenia - diagnosis | bleeding time: abn; ritoceiten: ok; adp: abn |
Glandzman Thrombasthenia - managment | plt transfusion(no cure) |
Vonwillebrand disease - general | autosomal dominant; defective vWF most common bleeding disorder |
Vonwillebrand disease - manisfestations | spontaneous bleeding; menorrhagia |
Vonwillebrand disease - diagnosis | Low vWF; Plt count: ok; bleeding time: ok; plt aggr: normal; abnormal aPTT(<25%); decrease Factor 8 |
Vonwillebrand disease - treatment | DDAVP(vasopressin stim endo to dump out vWF for: Type 1,3); FFP, cryoprecipitate. |
Vonwillebrand disease - type 1 | most common; decrease in vWF |
Vonwillebrand disease - type 2a | qualitative abnormality in protein that prevents multimer formation |
Vonwillebrand disease - type 2b | qualitative abnormality in protein causing rapid clearance of large multimeric forms |
Vonwillebrand disease - type 3 | autosomal recessive disorder in which vWF is nearly absent |
Intrinsic Coagulation | F12-(kalkerin)>F12a; F11-(F12a)>F11a; F9-(F11a)>F9a; F10-(plt, ca, F9a, F8)>F10a; F2-(plt, ca, F10a, F5)> thrombin; Fibrinogen-(thrombin)>fibrin; F13-(thrombin)>F13a->cross links fibrin |
Extrinsic Coagulation | F7-(thromboplastin)>F7a; F10-(plt, ca, F7a)>F10a; F2-(plt, ca, F10a, F5)> thrombin; Fibrinogen-(thrombin)>fibrin; F13-(thrombin)>F13a->cross links fibrin |
PTT | Intrinsic pathway of coagulation; most sensitive to abnormals before F10 activation; heparin monitoring. Cephalin (negatively charged surface activates F11 and 12); Normal: 28-30s |
PT | Extrinsic pathway of coagualtion; sensitive to fibrinogen, prothrombin, F5, F7, and F10. Tissue factor added to whole plasma; INR=pt/control; normal=1. |
Hemophilia A - general | X-linked(30% mutations), most common hereditary dx of serious bleeding; deficient F8; 5-75%: mild bleeding, 1-5%:moderate; <1%: severe(hematuria) |
Hemophilia A - manifestations | easy bruising/bleeding/spont, hemarthroses |
Hemophilia A - Diagnosis | Bleeding time: ok, PTT: prolonged; PT: normal; F8: low |
Hemophilia A - treatment | F8 concentrates (recombinant) |
Hemophilia B - general | x-linked; F9 deficient(christmas factor); 1/3 quality, 2/3 quanity. |
Hemophilia b - manifestations | easy bruising/bleeding/spontaneous; hemarthroses |
Hemophilia B - Diagnosis | bleeding time: ok; ptt:prolonged; pt:ok; low F9 |
Hemophilia B - Treatment | F9 concentrations |
Hemophilia C - general | Autosomal recessive; ashkenazi jews, F11 deficient |
Hemophilia C - diagnosis | bleeding time: ok; PTT: prolonged; pt: ok; F11: low |
Hemophilia C - manifestations | mild bleeding: post op |
Hemophilia C - Treatment | FFP as needed |
Afribrinogenemia | rare, variable, in presentation, replace with FFP |
F12 deficiency | prolonged ptt; not associated with increased bleeding |
Bleeding caused Liver disease | vitamin K defendant factors are reduced; increase fibrinolysis; Alpha2-antiplasmin is not longer made(inhibits plasmin); give FFP |
Vitamin K deficiency | acquired defect leading to bleeding; intake from diet(leafy green veggies); intestinal bct; Abs kills bct, wardarin and coumadin inhibit vitamin K metabolism. |
DIC - general | consumption of coagulation proteins that causes excessive bleeding caused by sepsis, tissue injury, OB complication, cancer. 50-60% die |
DIC - Manifestations | Consumption of coag factors and activation of D-Dimer(Accelerates plasminogen->plasmin; bleeding; micro thrombosis |
DIC - Diagnosis | Hypofibrinogenemia; elevated fibrin degradative products(D-Dimer); thrombocytopenia; PT and PTT:prolonged |
DIC - management | Prevention(ab); heparin(stops the consumption of clotting factors). |
Lupus Anticoagulant | Acquired/congential; an IgM or IgG produces prolonged PTT by binding phospholipid in the invitro assay; does not cause bleeding disorder unless second disorder exists |
Acquired defects leading to hypercoagulable state | Cancer: some colon CA release pro-coagulable products; Estrogens: being older and smoking increase this; pregnancy: fibrinigen levels double in 3rd tri; anticardiolipin abs: autoimmune diseases, unknown reason. |
Antithrombin III deficiency | congenital disorder causing a hypercoaguable state; Works synergistically with heparin to block thrombin, F10a, F9a, and F11a. end most common to F5 leiden. |
Factor V Leiden | A defect on the F5 leiden does not allow C reactive protein to bind and deactivate it. This causes very large clots to form once they start(congenital). |
Protein C defciency | Protein C binds F5 and F8 and in activates them to control the clotting process; clotting is uncontrolled in this congenital disease; can be quality or quanity. |
Protein S deficiency | Protein S acts as a cofactor for C. clotting is uncontrolled in this congenital disease. |
Coumadin | Disrupts vitamin K utilization; Vitamin K dependant Factors: 2,7(most effected),9, 10; oral admin; slow onset; Monitor w/ PT |
Heparin | Blocks thrombin, F10a, F9a, and F11a synergystically with antithromben III; IV or subq admin; fast onset; high variability except LMW; monitor with PTT |
Thrombomodulin | When thrombin is activated it binds to thrombomodulin and activates protein C+S to stop clotting; released by endothelium. |
Petechiae | <.5cm; usually from thrombocytopenia; not a functional problem. |
Purpura | >=5cm; superficial dermatological bleeding; can be problem with plts, or vascular abn; |
Ecchymosis | Subq bleeding |
Hemorrhage | blood loss from vascular |
Integrin | Blocks 2b3a, Iv admin |
TPA | catalyst for Plasminogen to plasmin; released by endothelial |
Thromboxane A2 | Arachadonic Acid from plts is turned into thromboxane A2 which causes plt aggregation and vasoconstriction. COX1>2 inhibition. |
PGI2 | Arachadonic Acid from endothelial cells is turned into PGI2 which causes decrease plt activation and vasodilation. COX2>1 inhibition. Less affected by COX-1 (high cox turnover)inhibition than Thromboxane A2. |
COX-1 Inhibitors | Stops Thomboxane A2, PGE2, and prostaglandin synthesis |
COX-2 inhibitors | stops PGI2 and prostaglandin synthesis. |
PGI2 | Arachadonic Acid from endothelial cells is turned into PGI2 which causes decrease plt activation and vasodilation. COX2>1 inhibition. Less affected by COX-1 (high cox turnover)inhibition than Thromboxane A2. |
COX-1 Inhibitors | Stops Thomboxane A2, PGE2, and prostaglandin synthesis |
COX-2 inhibitors | stops PGI2 and prostaglandin synthesis. |
Types of Hemoglobin | HbA(alph2, beta2) 96%; HbA2(alpha2. delta2) 3%; HbF: (alpha2, gamma2) fetal; HbS (SS) (alpha2, beta2mutation) |
RBC count | 4(women)-5(men)10x6/ul; |
Hemoglobin | 12-16 gm/dl, 14-17 gm/dl, women-men |
Hematocrit | (Hgx3)=;37%-47%, 40%-54%, women-men |
Mean corpuscular Volume | 87-103 ul |
Mean corpuscular hemoglobin | 26-24 pg/cell or .40-.53 fmol/cell |
Mean corpuscular hemoglobin concentration | 31-37 g/dl should be 1/3 of the cell |
reticulocyte | .5-2.5%, .5-1.5%, women-men |
Decrese in quality of RBC's | Hct: <37%, 40%; Hg: <12 gm/dl, <13.5 gm/dl |
Iron metabolism | Stored in liver and Macrophages as ferritin(indicator of total body iron); heme iron absorption 10%, non-heme iron 1%; average daily absorption 1mg/day and daily loss equal each other. |
Ferritin lab value | 20-400 ng/ml |
Iron Deficiency - general | Microcytic-hypochromic anemia; causes: chronic bleeding 2-4ml/day, medications(aspirin), dietary causes, pregnancy. clinical findings when hg is 7-8 gm/dl. |
Iron deficiency - Manifestations | Classic manifestations: pale, weakness, SOB, fatigue, brittle nails, paraesthesia, sore tongue, decrease appetite, weight loss, increase HR, decrease BP, Pica, cheilosis(more with B deficiency). |
Iron deficeincy - diagnosis | total iron: decreased; Ferritin(can be normal if inflammatory disease): decresed; TIBC: increased(liver compensation); % sat: decreased; MCV: decreased; MCHC: decreased |
Iron Deficeincy - management | oral iron: ferrous sulfate 325 mg TID = 150mg/day pure Fe(up to 10mg absorbed)4-6wks 1/2 normal, 2 mo. normal, continue 3-6 mo to replenish; Parenteral iron: only if intol. to GI absorb.can cause anaphylaxis, IM= stain; Packed RBC best 1ml=1mg Fe |
Anemia of Chronic Disease - general | Microcytic-hypochromic anemia; causes: CHF, cancer, IBD, liver disease; RBC survival reduced; BM fails to compensate; iron metabolism fails |
Anemia of Chronic Disease - manifestations | manifestations relating to causative condition; classic manifestations: pale, weakness, SOB, fatigue, brittle nails, paraesthesia, sore tongue, decrease appetite, weight loss, increase HR, decrease BP, Pica, cheilosis(more with B deficiency). |
Anemia of Chronic Disease - Diagnosis | Hct, hg, MCV, MCHC: decreased; reticulocytes; serum iron: low; TIBC: low(liver is not as active); Ferratin: increased or normal; % sat: decreased |
Anemia of Chronic Disease - Management | nothing; treat chronic disease; EPO 30,000units/wk |
Alpha Thalassemias - General | Microcytic-hypochromic anemia; gene deletion (reduced alpha chain syn.); hereditary; asian and chinese descent |
Alpha Thalassemias - manifestations | 3 genes normal: heme normal, carrier; 2 genes normal: alpha trait(form of minor); 1 gene normal: Hg H disease; chronic hemolytic anemia(variable severity) pallor, splenomegaly; 0 genes normal:still born, hydrop fetalis |
Alpha Thalassemias(trait or minor) - Diagnosis | Trait or minor(mild anemia): hct:28-40%, MCV:60-75; MCHC: dec.; RBC: normal, inc.; Target cells:yes; Electropharesis: normal |
Alpha Thalassemias(Hg H disease) - Diagnosis | hct:22-32%, MCV:60-70; MCHC: dec.; Target cells:yes; Electropharesis: abn |
Beta Thalassemia - general | Microcytic-hypochromic anemia; point mutations-premature chain termination resulting in reduced or absent beta-globin chain synthesis; Mediterranean; hetero: minor; homo: major; severe anemia develops at 6 months requiring transfusions(fetal hg) |
Beta Thalassemia minor - manifestations | modest anemia |
Beta Thalassemia Major - manifestations | severe anemia |
Beta Thalassemia minor - Diagnosis | MCHC, MCV: decreased, target cells, basophilic stippling, reticulocyte: normal or increased |
Beta Thalassemia major - Diagnosis | sever poikilocytosis, MCV, MCHC: decreased, target cells, basophilic stippling |
Beta Thalassemia minor - management | no treatment |
Beta Thalassemia major - management | regular transfusion schedule(hemaochromatosis if to much iron); folate; splenectomy; iron chelation(deferipone; Bm transplant |
Alpha Thalassemia (trait) - management | no treatment |
Alpha Thalassemia (Hg H disease) - management | folate; avoid iron |
Sideroblastic Anemia - general | Microcytic-hypochromic Anemia; hereditary/hetero/acquire; hemoglobin syn. disorders; fails to incorporate heme into protoporphyrin; iron accumulates |
Sideroblastic Anemia - manifestations | Classic anemia manifestations: pale, weakness, SOB, fatigue, brittle nails, paraesthesia, sore tongue, decrease appetite, weight loss, increase HR, decrease BP, Pica, cheilosis(more with B deficiency). |
Sideroblastic Anemia - diagnosis | Ringed sideroblasts(nucleated RBC with iron in cytoplasm) and inc. iron in BM; MCV: variable; MCHC: dec.; iron: inc.; % sat. inc.; can be caused due to decrease in B6(malnourished). |
Vitamin B12 Deficiency - general | Macrocytic-normochromic anemia; B12(colbalamin) is a cofactor for homosycteine->methionine, methylmolanic acid->succybyl CoA; in animal protein; transported by Transcobalamin(1,2,3); causes: lack of intrinsic, dietary, iatrogenic(surgery), age(atrophy) |
Vitamin B12 Deficiency - manifestations | Slow onset(liver storage:2000-5000mcg, lose 3-5 mcg/day); hg 7-8gm/dl=classical signs; neurological: methylmelonic build-up; lat. adn post columns of SC demyelination(proprio, vibe, fine, integrate) irreversible; |
Vitamin B12 Deficiency - diagnosis | Hg, Hct: dec.; MCV: inc.; MCHC: ok; aniso-poikilo-cytosis; hypersegmented neutrophil(mean lobe: >4); reticulocyte: dec.; BM: blasts(may affect all cells); Vit B12(transcobalamin 2): dec.; Methylmalonic: inc.; schilling: radio active B12 urine test; |
Vitamin B12 Deficiency - treatment | 1000mg q day x 7days, then weekly then monthly |
Folic acid deficiency - general | folic acid is important to DNA syn.; causes: dietary; body store 5000mcg; 50-100 mcg/day; |
Folic acid deficiency - manifestations | similar to classic manifestations; No neurological like B12 |
Folic acid deficiency - diagnosis | HG, Hct: dec.; MCV: inc.; nomral; MCHC: ok; aniso-poikilo-cytosis; macro-ovalocyte;hypersegmented neutrophil(mean lobe: >4); folate: dec.; B12: ok |
Folic acid deficiency - treatment | folic acid |
Aplastic Anemia - general | Normocytic/normochromic anemia; bone marrow hypoplasia; erythrocyte stem cells: underdeveloped, defective, absent; causes: radiation; medication; autoimmune; Fanconi: genetic aplastaic with early onset; idiopathic: 80% are >50yo |
Aplastic Anemia - manifestations | Classic as RBCs get low; deficiency of all cells(plts and WBCs) |
Aplastic Anemia - diagnosis | pancytopenia; MCV, MCHC: ok; BM: hypocellular |
Aplastic Anemia - treatment | whole blood transfusions; severe: BM transplant |
Sickle cell Anemia - general | Normocytic/normochromic anemia; autosomal recessive; point mutation(T->A): Glutamine to valine; 8% of African americans have 1 gene; |
Sickle cell pathophysiology | In low po2, acidic environments RBCs with high levels of Hbs(HBa and HBf are inhibitory)go into the deoxy, sickle form, this causes permanent membrane damage; The more damage the stickier they get and the less likelihood of returning to the normal shape |
Sickle cell anemia - manisfestations | Chronic hemolytic anemia, jaunidce, pigmented gallstones, slpenomegally(child); infartion:kidney, heart, liver, lungs, GI, spleen; classic signs |
Sickle cell anemia - diagnosis | Hct: 20-30%; sickled: 5-50%; reticulcytes:10-25%; WBCs: inc.; hyposplenism; Bilirubin: inc.; electrophoresis: abn |
Sickle cell anemia - treatment | Avoid dec. po2, dehydration; pain control, Hydroxyurea: 500-750 mg/day (stimulates fetal hemoglobin) |
Herditary spherocytosis - general | autosomal dominant-variable severity(defective spectrin); disorder of red cell membrane; chronic hemolytic anemia(spleen); decrease surface to volume ratio(no biconcave shape) |
Herditary spherocytosis - manifestations | Classic signs |
Herditary spherocytosis - diagnosis | Hct, Hg, MCV: decreased; MCHC: increased(onlt anemia with microcytosis and hyperchromia); reticulocytes; spherocytes; bilirubin |
Herditary spherocytosis - treatment | no cure, folic acid; splenecotomy |
Glucose-6-phophate Dehyrdrogenase Deficiency | x-linked recessive; 10-15% African American males; G6PD is important in GSH synthesis which protects Hg from oxidative denaturation(Heinz bodies); aspirin, sulfas, and nitrates bind G6PD; reticulocytes and bilirubin inc.(hemolysis); avoid triggers |
Created by:
bmg4
Popular Medical sets